Subcutaneous abatacept in rheumatoid arthritis: Current update

Expert Opinion on Biological Therapy

Volumn 15, Issue 8, 2015, Pages 1221-1230

  Keystone, Edward ^a   Alkhalaf, Abdulaziz ^b   Makkawy, Mosaab ^c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Ministry of Health   (Saudi Arabia)

Author keywords

Abatacept; Biologic therapy; Rheumatoid arthritis; Subcutaneous

Indexed keywords

ABATACEPT; PNEUMOCOCCUS VACCINE; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; AUTOIMMUNE THYROIDITIS; BASAL CELL CARCINOMA; BREAST CANCER; CANCER GROWTH; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHEMA NODOSUM; GASTROENTERITIS; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LUNG CARCINOMA; MELANOMA; MULTIPLE ORGAN FAILURE; NURSING; OPPORTUNISTIC INFECTION; PERITONITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREGNANCY; PROSTATE CANCER; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SJOEGREN SYNDROME; SMALL CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUBERCULOSIS; URINARY TRACT INFECTION; UTERUS CANCER; VACCINATION; ANIMAL; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; IMMUNOLOGY; METABOLISM; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ABATACEPT; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCONJUGATES; INJECTIONS, SUBCUTANEOUS; TREATMENT OUTCOME;

EID: 84936929259     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1065248     Document Type: Article

References (39)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27(2):269-81
2. McInnes IB, O'Dell JR. State-of-The-art: rheumatoid arthritis [published erratum appears in Ann Rheum Dis 2011;70:399]. Ann Rheum Dis 2010;69:1898-906
3. Singh JA, Furst DE, Bharat A, et al. Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
4. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological diseasemodifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73(3):516-28
5. Panayi GS, Corrigall V, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum Dis Clin North Am 2001;27:317-34
6. VanderBorght A, Geusens P, Raus J, et al. The autoimmune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum 2001;31:160-75
7. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16
8. Udagawa N, Kotake S, Kamatani N, et al. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-9
9. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53
10. Stuart RW, Racke MK. Targeting T cell costimulation in autoimmune disease. Exp Opin Ther Targets 2002;6:275-89
11. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9
12. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13
13. Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28/CTLA- 4 and oligomerization of CD80/ CD86 regulate T cell costimulatory interactions. J Biol Chem 1996;271:26762-71
14. Corbo M, Valencia X, Raymond R, et al. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity. Ann Rheum Dis 2009;68:S574
15. Bristol-Myers Squibb. Orencia prescribing information. Available from: http://packageinserts.bms.com/pi/pi- orencia.pdf [Last accessed December 2013]
16. Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854-64
17. Genovese M, Pacheco-Tena C, Covarrubias A, et al. Subcutaneous abatacept: long-term data from the ACQUIRE trial. Arthritis Rheum 2012;64(10 Suppl):S201
18. Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis 2012;71:38-44
19. Kaine J, Gladstein G, Strusberg I, et al. Subcutaneous abatacept is effective and well tolerated, with low immunogenicity following temporary withdrawal and reintroduction in the ALLOW LTE. Arthritis Rheum 2011;63:S853
20. Genovese MC, Schiff M, Luggen ME, et al. Abatacept demonstrates consistent safety and sustained improvements in effi cacy through 4 years of open-label treatment in patients with an inadequate response to anti-TNF therapy. Arthritis Rheum 2009;60(Suppl 10):1689
21. Genovese MC, Schiff M, Luggen M, et al. Effi cacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54
22. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-63
23. Kremer JM, Russell AS, Emery P, et al. Abatacept demonstrates consistent safety and sustained improvements in effi cacy through 5 years of treatment in biologicnaïve patients with RA. Ann Rheum Dis 2009;68(Suppl 3):FRI0263
24. Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 2012;71:857-61
25. Weinblatt M, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2012;65:28-38
26. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73(1):86-94
27. Emery P, Burmetster GR, Bykerk VP, et al. Evaluation drug-frr remission with abatacept in early rheumatoid arthritis; study of 24 months from AVERT trial phase IIIb. Ann Rheum Dis 2015;74:19-26
28. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-16
29. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7
30. Alten R, Kaine J, Keystone EC, et al. Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): Integrated analysis of five clinical trials up to 4.5 years. Ann Rheum Dis 2011;70(Suppl 3):617
31. Alten R, Kaine J, Keystone EC, et al. Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure. Arthritis Rheum 2011;63:S150
32. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):1-60
33. Nash P, Nayiager S, Genovese M, et al. Immunogenicity, safety and efficacy of subcutaneous abatacept with or without MTX in patients with rheumatoid arthritis: the Phase III ACCOMPANY study. Arthritis Care Res (Hoboken) 2013;65(5):718-28
34. Simon TA, Smitten AL, Franklin J, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009;68:1819-26
35. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-15
36. Haggerty HG, Abbott MA, Reilly TP, et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 2007;34:2365-73
37. Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196-203
38. Nash P, Ludivico C, Delaet I, et al. Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous (IV) loading dose. Arthritis Rheum 2011;63(Suppl 10):S151
39. Schiff M, Alten R, Weinblatt M, et al. Weekly subcutaneous abata cept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose. Arthritis Rheum 2012;64(Suppl 10):S1076